10.00 AM - 11.30 AM
The fast-growing pace of the pharmaceutical industry raised the pressure on stakeholders to enable innovation and provide technologies to attend to people's needs as rapidly and safely as possible. One of the latest developments in the pharmaceutical industry is associated with targeted therapies, including monoclonal antibodies (mAbs). mAbs revolutionized their field since they were first developed in the 1980s. A fast-growing multibillion-dollar market was formed. Despite their excellent results, many mAbs are expensive and might not be distributed to the population because of their high price and, consequently, low efficiency.
This work proposes six studies directly or indirectly related to different stages of the life cycle of mAbs, including the phases of (i) research & development (R&D), (ii) registry, (iii) pricing, and (iv) incorporation. It aims to study the market of mAbs from development to the incorporation of the drugs into healthcare systems. It includes analyses of the patents, patent holders, producers, indications of use, incorporation of technologies in three countries, and a case study. The case study evaluates rituximab to treat chronic lymphocytic leukemia (CLL). Hopefully, this work will be a step toward fairer access to healthcare technologies worldwide.
For more information, please email the Graduate Research School or phone 0746 31 1088.